6-alkylamino-2,2'-disubstituted-7,8-disubstituted-2H-1-benzopyran derivatives as 5-lipoxygenase inhibitor
申请人:Gong Young-Dae
公开号:US20050203145A1
公开(公告)日:2005-09-15
When a multi-step process reaction is carried out in a solution, it generally requires several treatments and purification procedures to go through with after the reaction, however, the inventive method for preparing 2,2′-disubstituted-3,4-dihydro-7,8-disubstituted-6-amino benzopyran derivative using a solid-phased synthetic method simplifies the treatment and purification procedures after the reaction, which makes possible to efficiently construct numerous drug-like libraries. In particular, since the inventive method of the present invention comprises the steps of introducing a carbonate linker of formula 2 into Wang resin used as a common solid support (Step 1); synthesizing various benzopyran in a carbamate form of formula 3 as a key intermediate by reacting various amino benzopyran derivatives with the carbamate resin of formula 2 (Step 2); synthesizing 2,2′-disubstituted-3,4-2H-6-substituted benzopyran resin of formula 4 (Step 3); and synthesizing 2,2′-disubstituted-3,4-2H-6-alkylamino benzopyran derivative of formula 1 using a dichloromethane solution containing TFA or an organic solvent containing an organic acid, the inventive method is capable of efficiently synthesizing various 2,2′-disubstituted-3,4-2H-6-alkylamino benzopyran derivatives. Consequently, the present invention has developed a new technique for constructing 2,2′-disubstituted-3,4-2H-6-alkylamino benzopyran library using a solid-phase parallel synthetic method and makes increased the applicability of combinatorial chemical synthetic method. Further, 2,2′-disubstituted-3,4-2H-6-alkylamino benzopyran derivative prepared by the inventive method has a high inhibitory effect to 5-lipoxygenase (5-LO) activity, and therefore, can be effectively used for developing a new propylactic or therapeutic drug for leukotriene activation-related diseases such as chronic inflammation, rheumatic arthritis, colitis, asthma and psoriasis.
当多步骤反应过程在溶液中进行时,通常需要进行几次处理和纯化程序才能完成反应后的步骤,然而,使用固相合成方法制备
2,2'-二取代-3,4-二
氢-7,8-二取代-6-
氨基
苯并
吡喃衍
生物的创新方法简化了反应后的处理和纯化程序,从而能够有效地构建大量类似药物的文库。特别是,由于本发明的创新方法包括以下步骤:将式2的
碳酸酯连接体引入作为常见固体支持的Wang
树脂中(步骤1);通过将各种
氨基
苯并
吡喃衍
生物与
碳酸酯树脂(式2)反应,合成各种以
氨基甲酸酯形式(式3)为关键
中间体的
苯并
吡喃(步骤2);合成式4的
2,2'-二取代-3,4-2H-6-取代
苯并
吡喃
树脂(步骤3);并使用含有
三氟乙酸(T
FA)的
二氯甲烷溶液或含有有机酸的有机溶剂合成式1的
2,2'-二取代-3,4-2H-6-烷基
氨基
苯并
吡喃衍
生物,该创新方
法能够有效地合成各种
2,2'-二取代-3,4-2H-6-烷基
氨基
苯并
吡喃衍
生物。因此,本发明已经开发了一种使用固相并行合成方法构建
2,2'-二取代-3,4-2H-6-烷基
氨基
苯并
吡喃文库的新技术,并增加了组合
化学合成方法的适用性。此外,通过创新方法制备的
2,2'-二取代-3,4-2H-6-烷基
氨基
苯并
吡喃衍
生物对5-脂
氧酶(5-LO)活性具有高抑制作用,因此,可以有效用于开发用于治疗
白三烯激活相关疾病(如慢性炎症、风湿性关节炎、结肠炎、哮喘和
银屑病)的新型预防或治疗药物。